Pharmaceutical - Allergan

Filter

Current filters:

Allergan

Popular Filters

1 to 25 of 54 results

NICE makes preliminary recommendation on Allergan's Ozurdex for macular edema

NICE makes preliminary recommendation on Allergan's Ozurdex for macular edema

20-02-2015

The UK’s National Institutes of Health and Care Excellence has recommended Ozurdex (dexamethasone),…

AllerganDexamethasoneOphthalmicsOzurdexPharmaceuticalRegulationUK

Actavis’ fourth-qtr 2014 beats expectations

Actavis’ fourth-qtr 2014 beats expectations

18-02-2015

Ireland-headquartered generics major Actavis posted better-than-expected fourth-quarter and full-year…

AccountancyActavisAllerganFinancialForest LaboratoriesGenericsPharmaceuticalThomson ReutersUSA

Valeant admits disappointment at loss of takeover target Allergan to Actavis

Valeant admits disappointment at loss of takeover target Allergan to Actavis

19-11-2014

Canadian drugmaker Valeant International has admitted that the loss of hostile takeover target Allergan…

ActavisAllerganCanadaMergers & AcquisitionsPharmaceuticalValeant

Allergan agrees to $66 billion acquisition by Actavis

Allergan agrees to $66 billion acquisition by Actavis

17-11-2014

Confirming what were becoming ever stronger rumors over the weekend, Ireland-headquartered Actavis this…

ActavisAllerganMergers & AcquisitionsPharmaceuticalUSAValeant Pharmaceuticals International

Allergan is reportedly in takeover talks with Actavis

Allergan is reportedly in takeover talks with Actavis

07-11-2014

Botox maker Allergan is reportedly in merger talks with Ireland-headquartered generics major Actavis,…

ActavisAllerganMergers & AcquisitionsPharmaceuticalUSA

Allergan posts strong results which provoke reaction from potential suitor Valeant

Allergan posts strong results which provoke reaction from potential suitor Valeant

27-10-2014

Botox maker Allergan has reported strong quarterly results amid an ongoing buyout dispute with Quebecois…

AllerganBotoxBusiness FinancePharmaceuticalUSAValeant

Allergan says Pershing’s additional requests for meeting is not “meaningful development”

Allergan says Pershing’s additional requests for meeting is not “meaningful development”

15-09-2014

Hostile takeover target Allergan has said that value is what “really matters” in response to Pershing…

AllerganCanadaFinancialLegalPharmaceuticalUSAValeant Pharmaceuticals International

Allergan’s Ozurdex approved for DME in Europe

Allergan’s Ozurdex approved for DME in Europe

02-09-2014

Allergan revealed today that the European Commission has extended the marketing authorization for Ozurdex…

AllerganEuropeOphthalmicsOzurdexPharmaceuticalRegulation

Pershing Square and other shareholders call for special meeting regarding Allergan hostile bid

Pershing Square and other shareholders call for special meeting regarding Allergan hostile bid

23-08-2014

Pershing Square Capital Management, the largest shareholder of Allergan, which is the subject of a $53…

AllerganManagementMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Allergan names Jim Hindman chief financial officer

Allergan names Jim Hindman chief financial officer

19-08-2014

Allergy specialist Allergan has appointed Jim Hindman as chief financial officer, effective immediately,…

AllerganBoardroomBusiness FinanceBusiness FinanceChief financial officerJim HindmanPharmaceuticalUSA

Allergan acquires LiRIS program from TARIS Biomedical

Allergan acquires LiRIS program from TARIS Biomedical

14-08-2014

US drugmaker Allergan has closed a transaction to acquire worldwide rights to privately-held TARIS Biomedical’s…

AllerganGenito-urinaryGlobalLicensingLiRISPharmaceuticalTARIS Biomedical

Allergan attacks Valeant’s financial results

Allergan attacks Valeant’s financial results

06-08-2014

US Botox maker Allergan, the subject of a hostile $53 billion takeover attempt by Canada’s Valeant…

AllerganBusiness FinanceCanadaFinancialMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Allergan sues Valeant and Pershing Square, alleging insider trading

Allergan sues Valeant and Pershing Square, alleging insider trading

02-08-2014

US Botox maker Allergan, the subject of a hostile $53 billion takeover attempt by Canada’s Valeant…

AllerganBusiness FinanceLegalMergers & AcquisitionsPharmaceuticalUSAValeant Pharmaceuticals International

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

21-07-2014

Botox maker Allergan has reported its second quarter operating results while also announcing that it…

AllerganAllerganBotoxFinancialPharmaceuticalUSA

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

Allergan rejects Valeant’s latest bid

Allergan rejects Valeant’s latest bid

24-06-2014

Botox maker Allergan has announced that its Board of Directors has unanimously determined that Valeant…

AllerganBusiness FinanceBusiness FinanceEconomicsFinanceMergers & AcquisitionsPharmaceuticalStock marketUSAValeant Pharmaceuticals

Valeant goes hostile in $53 billion bid for Allergan

Valeant goes hostile in $53 billion bid for Allergan

18-06-2014

Canada’s Valeant Pharmaceuticals International has today commenced an exchange offer for the common…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Pershing Square files law suit over Allergan’s rights plan

Pershing Square files law suit over Allergan’s rights plan

15-06-2014

William Ackman's Pershing Square Capital Management has filed a law suit in the Delaware Court of Chancery…

AllerganLegalMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Allergan board again rejects revised unsolicited takeover bid from Valeant

Allergan board again rejects revised unsolicited takeover bid from Valeant

10-06-2014

US Botox-maker Allergan says that its board of directors, after consulting with its independent financial…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

Valeant goes even further, upping recently sweetened offer for Allergan

Valeant goes even further, upping recently sweetened offer for Allergan

02-06-2014

Even before it received an official response from its takeover target US Botox-maker Allergan, acquisitive…

AllerganMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals International

1 to 25 of 54 results

Back to top